Isomorphic Labs raises $2.1B

Isomorphic Labs said on May 12 that it had raised $2.1 billion in Series B funding, giving the Alphabet-backed drug discovery company new capital to expand its AI drug-design engine and move more programs toward the clinic. The company said Thrive Capital led the round, with existing backers Alphabet and GV joining new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The financing follows a $600 million external round announced on March 31, 2025. The new raise puts fresh attention on a company founded by Demis Hassabis to turn advances from DeepMind and AlphaFold into drug candidates. ### Why did this round stand out? The $2.1 billion figure is unusually large for a drug discovery startup, and Isomorphic Labs said it would use the money to scale its business globally and progress its drug candidate pipeline. The company tied the round directly to its in-house AI drug design engine, known as IsoDDE. (isomorphiclabs.com) Thrive Capital’s role also mattered because the firm had already led Isomorphic Labs’ first outside fundraising in 2025. In that earlier round, Isomorphic Labs said Thrive led a $600 million financing that also included GV and follow-on capital from Alphabet. ### What exactly is Isomorphic Labs building? (isomorphiclabs.com) Isomorphic Labs was created in November 2021 as an Alphabet company focused on an AI-first approach to drug discovery. In announcing the company, Hassabis said AlphaFold2 had shown how AI could model biology and help accelerate biomedical research. The company now describes its core platform as a unified drug design engine that can generate candidates across multiple therapeutic areas and drug modalities. (isomorphiclabs.com) In its January 2026 announcement with Johnson & Johnson, Isomorphic Labs said that capability spans small molecules, antibodies, peptides and molecular glues. (isomorphiclabs.com) ### Which drugmakers are already working with it? Isomorphic Labs said on January 7, 2024 that it had signed strategic collaborations with Eli Lilly and Novartis. The company said those two partnerships had the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties from future drug sales. (isomorphiclabs.com) Johnson & Johnson joined that list on January 20, 2026. Isomorphic Labs said the collaboration with J&J was cross-modality and multi-target, combining its AI-first discovery approach with the drugmaker’s experience in target biology and development. ### When are the first AI-designed drugs supposed to reach human testing? (isomorphiclabs.com) Demis Hassabis said in January that Isomorphic Labs expects to have its first clinical trials by the end of 2026, according to Reuters. That set a concrete timetable for a company that has spent the last two years building partnerships, internal programs and its design platform. (isomorphiclabs.com) The company’s May 12 funding announcement did not give a new trial date, but it said the capital would help progress its drug candidate pipeline. That language is consistent with the end-2026 target already outlined by Hassabis. ### What does the investor list say about this market? (marketscreener.com) MGX, Temasek and the UK Sovereign AI Fund appeared in Isomorphic Labs’ May 12 announcement as new investors alongside CapitalG, Alphabet and GV. Their participation shows that the company drew support not only from venture capital but also from sovereign and strategic pools of capital. (isomorphiclabs.com) The company’s recent announcements have also emphasized specific research programs and named pharmaceutical partners rather than consumer health products. In 2024 and 2026, Isomorphic Labs disclosed collaborations with Eli Lilly, Novartis and Johnson & Johnson, each tied to defined drug-discovery work. (isomorphiclabs.com) ### What happens next? May 12 is now the marker for Isomorphic Labs’ biggest financing to date, and the next milestone the company has put into the public record is clinical entry by the end of 2026. Between now and then, its named partners include Eli Lilly, Novartis and Johnson & Johnson, while the new capital is earmarked for IsoDDE, global expansion and pipeline progress. (isomorphiclabs.com 1) (isomorphiclabs.com 2)